Autopsy report · NCT01292083

Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery

“No accrual last 2 years”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Na

Sponsor

University of Southern California

Sponsor type

University, hospital or other

Conditions

Recurrent Breast Cancer; Stage IA Breast Cancer; Stage IB Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer

Interventions

azacitidine; laboratory biomarker analysis; immunohistochemistry staining method; polymerase chain reaction; western blotting; nucleic acid sequencing

Participants

0

Trials that died the same way

• Paclitaxel-induced Polyneuropathy in Breast Cancer: Early Detection, Risk Factors, Quality of Life and Lifestyle Outcomes
  “No accrual” (73% match in meaning)
• A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer
  “No accruals” (71% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (70% match in meaning)
• Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
  “Lack of accrual” (68% match in meaning)
• Afatinib in Advanced Refractory Urothelial Cancer
  “Unable to meet accrual goal after several years” (68% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.